Chronic Obstructive Pulmonary Disease Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Tetherex, Mereo, Synairgen, GSK

 Breaking News
  • No posts were found

Chronic Obstructive Pulmonary Disease Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Tetherex, Mereo, Synairgen, GSK

September 11
22:38 2023
Chronic Obstructive Pulmonary Disease Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Tetherex, Mereo, Synairgen, GSK
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 65+ key pharma and biotech companies are working on 70+ pipeline drugs in the Chronic Obstructive Pulmonary Disease therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Chronic Obstructive Pulmonary Disease Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Chronic Obstructive Pulmonary Disease Market. 

The Chronic Obstructive Pulmonary Disease Pipeline report embraces in-depth commercial, regulatory, and Chronic Obstructive Pulmonary Disease clinical trial assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the emerging Chronic Obstructive Pulmonary Disease drugs, including the mechanism of action, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Chronic Obstructive Pulmonary Disease Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for Chronic Obstructive Pulmonary Disease treatment and the aggregate therapies developed by major pharma companies.

  • It accesses the different Chronic Obstructive Pulmonary Disease therapies segmented into early-stage, mid-stage, and late-stage of clinical development.

  • It outlines the major Chronic Obstructive Pulmonary Disease companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the Chronic Obstructive Pulmonary Disease drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Chronic Obstructive Pulmonary Disease therapeutic market.

Chronic Obstructive Pulmonary Disease Therapeutics Landscape

Many people with COPD have mild forms of the disease for which little therapy is needed other than smoking cessation. Even for more advanced stages of the disease, effective therapy is available that can control symptoms, slow progression, reduce the risk of complications and exacerbations, and improve the ability to lead an active life. The goal of treating COPD is to help the person breathe easier and get back to regular activities; many treatments and lifestyle approaches can help. The patient may also try some natural and alternative treatment options. COPD treatment focuses on relieving symptoms, such as coughing, and breathing problems, and avoiding respiratory infections. The treatments are often based on the stages of COPD. There are certain lifestyle changes required to prevent COPD. Quitting smoking is an essential step in any treatment plan for COPD. Stopping smoking can keep COPD from getting worse and reducing the ability to breathe.

Pharmacotherapy for COPD consists of maintenance and reliever medications. Maintenance medications included inhaled corticosteroid (ICS), long-acting beta-agonist(LABA), fixed-dose combination ICS+LABA, tiotropium (TIO), and inhaled ipratropium or fixed-dose combination ipratropium+albuterol (collectively referred to as ipratropium[IPR]).

To further improve the treatment outlook, approx. 65+ key companies developing the therapies for Chronic Obstructive Pulmonary Disease. Currently, AstraZeneca is leading the therapeutics market with its Chronic Obstructive Pulmonary Disease drug candidates in the most advanced stage of clinical development.

Chronic Obstructive Pulmonary Disease Companies Actively Working in the Therapeutic Market Include:

  • Sanofi

  • AstraZeneca

  • Amgen

  • Synairgen

  • GlaxoSmithKline

  • Eisai

  • Meridigen Biotech

  • Chiesi

  • EmeraMed Limited

  • Verona Pharma

  • Tetherex Pharmaceuticals

  • Mereo BioPharma

And Many Others

Emerging and Marketed Chronic Obstructive Pulmonary Disease Drugs Covered in the Report Include:

  • Ensifentrine: Verona Pharma

  • Benralizumab: AstraZeneca

  • SAR440340: Sanofi/Regeneron

  • CHF 6001: Chiesi Farmaceutici S.p.A

  • QBW-251: Novartis

  • Tezepelumab: AstraZeneca

  • Anti-ST2: Genentech

  • PBF-680: Palobiofarma

  • PUR1800: Pulamtrix

  • SNG001: Synairgen

  • GSK3923868: GlaxoSmithKline

And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Chronic Obstructive Pulmonary Disease Companies Working in the Market @

https://www.delveinsight.com/sample-request/chronic-obstructive-pulmonary-disease-copd-pipeline-insight

Analysis of Emerging Chronic Obstructive Pulmonary Disease Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued and inactive candidates

Route of Administration

Chronic Obstructive Pulmonary Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral

  • Intravenous

  • Subcutaneous

  • Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins

  • Small molecule

  • Monoclonal antibody

  • Peptide

Learn How the Chronic Obstructive Pulmonary Disease Treatment Outlook will Evolve with the Ongoing Clinical and commercial Activities in the Therapeutic Market @

https://www.delveinsight.com/sample-request/chronic-obstructive-pulmonary-disease-copd-pipeline-insight

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Chronic Obstructive Pulmonary Disease Treatment Patterns

4. Chronic Obstructive Pulmonary Disease – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Chronic Obstructive Pulmonary Disease Late Stage Products (Phase-III)

7. Chronic Obstructive Pulmonary Disease Mid-Stage Products (Phase-II)

8. Chronic Obstructive Pulmonary Disease Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Chronic Obstructive Pulmonary Disease Discontinued Products

13. Chronic Obstructive Pulmonary Disease Product Profiles

14. Major Chronic Obstructive Pulmonary Disease Companies in the Market

15. Key Products in the Chronic Obstructive Pulmonary Disease Therapeutics Segment

16. Dormant and Discontinued Products

17. Chronic Obstructive Pulmonary Disease Unmet Needs

18. Chronic Obstructive Pulmonary Disease Future Perspectives

19. Chronic Obstructive Pulmonary Disease Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report @

https://www.delveinsight.com/sample-request/chronic-obstructive-pulmonary-disease-copd-pipeline-insight

 

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports By DelveInsight

Obesity Market

“Obesity Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Obesity market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Obesity market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/market-research

Related Articles

Categories